These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 14960258)

  • 41. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC; Davis LE
    Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
    J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
    Paterson A; McCloskey E; Redzepovic J; Ott I; Gust R
    J Int Med Res; 2008; 36(3):400-13. PubMed ID: 18534121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of Bisphosphonates in Breast Cancer Therapy.
    Goldvaser H; Amir E
    Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale for the use of bisphosphonates in breast cancer.
    Kanis JA
    Acta Oncol; 1996; 35 Suppl 5():61-7. PubMed ID: 9142969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
    Paterson AH
    Cancer; 2000 Jun; 88(12 Suppl):3038-46. PubMed ID: 10898349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bisphosphonates in breast cancer.
    Mathew A; Brufsky A
    Int J Cancer; 2015 Aug; 137(4):753-64. PubMed ID: 24824552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
    Hillner BE; Weeks JC; Desch CE; Smith TJ
    J Clin Oncol; 2000 Jan; 18(1):72-9. PubMed ID: 10623695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dosing regimens and main adverse events of bisphosphonates.
    Body JJ
    Semin Oncol; 2001 Aug; 28(4 Suppl 11):49-53. PubMed ID: 11544576
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bisphosphonate therapy in the oncology setting.
    Lipton A
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):469-88. PubMed ID: 14662000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.
    Neville-Webbe Hl; Coleman RE
    Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
    Zojer N; Keck AV; Pecherstorfer M
    Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.